Detailed explanation of the correct dosage and usage of belimumab

Belimumab , as an innovative specific inhibitor of B lymphocyte stimulating factor (BLyS), brings new treatment hope to patients 5 years old and above with active systemic lupus erythematosus (SLE) and patients with active lupus nephritis who are receiving standard treatment. This drug can effectively regulate abnormal responses of the immune system by precisely targeting B lymphocytes, thereby alleviating patients' disease symptoms and improving their quality of life. However, to ensure the safety and effectiveness of belimumab, patients must strictly follow the correct dosage and usage.

For adults and childrenIn patients with SLE or lupus nephritis, the intravenous dose of belimumab is 10 mg/kg. During the first three doses, the interval was 2 weeks, and then adjusted to 4 weeks. The drug needs to be reconstituted, diluted, and given to the patient via intravenous infusion. The entire infusion process takes about an hour. Before an infusion, doctors may consider giving patients prophylactic medication to reduce the risk of infusion reactions and hypersensitivity reactions. During the infusion process, medical staff will closely observe the patient's reaction to ensure that the treatment is carried out safely.

For adultsSLE patients, the subcutaneous dose of belimumab is 200 mg once a week. This method of administration is relatively convenient, and patients can do it themselves at home or go to a medical institution to have it administered by medical staff. For pediatric SLE patients, the subcutaneous injection dose is adjusted according to body weight. Children weighing 40 kg or more are given 200 mg weekly; children weighing 15 kg to less than 40 kg are given 200 mg every 2 weeks.

For adults with lupus nephritis, the dose of subcutaneous belimumab varies. During the first 4 administrations, 400 mg is given each time (i.e., 2 200 mg injections), once a week. Thereafter, the dose is adjusted to 200 mg per week.

Subcutaneous injection of belimumab can be administered with a single-dose auto-injector or a single-dose prefilled syringe. The single-dose auto-injector is suitable for adults and children 5 to under 18 years old, while the single-dose prefilled syringe is suitable for adults 18 years and older. For children under 10 years old, belimumab must be given by a healthcare provider to ensure the injection is correct and safe.

Patients also need to be aware of some usage restrictions and precautions when using belimumab. Particularly in patients with severe active central nervous system lupus, belimumab is not recommended as its efficacy has not been evaluated in these patients. In addition, when injecting belimumab, patients should avoid injecting the drug into bruised, tender, red or hard skin to avoid affecting the absorption and effect of the drug.

In summary, the correct dosing and usage of belimumab is crucial to ensure therapeutic efficacy and patient safety. Patients should consult their doctor in detail to understand their specific medication regimen, and strictly follow the doctor's instructions. At the same time, you should pay close attention to your body's reaction during the medication. If you have any discomfort or abnormal symptoms, you should seek medical treatment in time and inform your doctor. With the correct dosage and use of medications, patients can better manage their disease and improve their quality of life.

Reference materials:https://www.drugs.com/benlysta.html